MARKET

ICAD

ICAD

ICAD US
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.44
-0.31
-2.64%
Closed 16:00 05/22 EDT
OPEN
11.76
PREV CLOSE
11.75
HIGH
11.84
LOW
11.29
VOLUME
170.62K
TURNOVER
--
52 WEEK HIGH
15.31
52 WEEK LOW
5.50
MARKET CAP
261.44M
P/E (TTM)
-10.2896
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ICAD stock price target is 14.70 with a high estimate of 16.00 and a low estimate of 13.50.

EPS

ICAD News

More
News Flash: 5 Analysts Think iCAD, Inc. (NASDAQ:ICAD) Earnings Are Under Threat
Simply Wall St. · 05/16 14:59
iCAD Highlights Presentation Of New Clinical Data From Xoft Brain IORT At ASCO May 29-31
iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced positive new clinical data supporting the Xoft® Axxent® Electronic
Benzinga · 05/13 21:19
iCAD Presents Positive New Clinical Data for Xoft Brain IORT at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Promising clinical research supports Xoft brain IORT as a viable treatment option for glioblastoma multiforme that may extend patients’ lives Overall survival benefit.
GlobeNewswire · 05/13 21:00
Edited Transcript of ICAD earnings conference call or presentation 11-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 05/12 17:09
iCAD EPS misses by $0.33, misses on revenue
iCAD (NASDAQ:ICAD): Q1 Non-GAAP EPS of -$0.20; GAAP EPS of -$0.59 misses by $0.33. Revenue of $6.55M (-3.2% Y/Y) misses by $1.16M. Press Release
seekingalpha · 05/12 01:04
iCAD Reports First Quarter 2020 Financial Results
GlobeNewswire · 05/11 21:01
icad Q1 EPS $(0.200) Misses $(0.130) Estimate, Sales $6.551M Miss $7.710M Estimate
icad (NASDAQ:ICAD) reported quarterly losses of $(0.200) per share which missed the analyst consensus estimate of $(0.130) by 53.85 percent. This is a 185.71 percent decrease over losses of $(0.070) per share from the
Benzinga · 05/11 20:01
iCAD, Inc.'s (NASDAQ:ICAD) Path To Profitability
Simply Wall St. · 05/06 12:38

Industry

Advanced Medical Equipment & Technology
+1.36%
Healthcare Equipment & Supplies
+1.09%

Hot Stocks

Symbol
Price
%Change

About ICAD

iCAD, Inc. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of its advanced image analysis and workflow products, and the Therapy segment consists of its radiation therapy products. The Company sells its products through its direct sales organization, as well as through various original equipment manufacturer partners, distributors and resellers. It develops and markets computer-aided detection (CAD) solutions for digital and film-based mammography systems. Its Axxent SPX Controller includes an optimized skin treatment arm customized for compatibility in confined patient treatment rooms in physician office-based facilities.
More

Webull offers kinds of iCAD Inc stock information, including NASDAQ:ICAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICAD stock news, and many more online research tools to help you make informed decisions.